The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function

The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function

Low density lipoprotein cholesterol (LDL-C) is a well-established risk factor for cardiovascular disease. Although there are several developed lipid lowering drugs such as statins and fenofibrates, many patients do not achieve an adequate response. Recently, proprotein convertase subtilisin/kexin ty...

Full description

Bibliographic Details
Main Authors: Patchareeya Amput, Christian McSweeney, Siripong Palee, Arintaya Phrommintikul, Siriporn C. Chattipakorn, Nipon Chattipakorn
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Proprotein convertase subtilisin/kexin type 9 inhibitor
Cholesterol
Cardiovascular function
Low density lipoprotein receptor
Heart
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332218347188
id doaj-e201c50f6d374f9797523c1394786317
record_format Article
spelling doaj-e201c50f6d374f9797523c13947863172021-05-21T04:16:14ZengElsevierBiomedicine & Pharmacotherapy0753-33222019-01-0110911711180The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular functionPatchareeya Amput0Christian McSweeney1Siripong Palee2Arintaya Phrommintikul3Siriporn C. Chattipakorn4Nipon Chattipakorn5Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, ThailandCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, United KingdomCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, ThailandCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, ThailandCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand; Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai 50200, ThailandCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand; Corresponding author at: Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.Low density lipoprotein cholesterol (LDL-C) is a well-established risk factor for cardiovascular disease. Although there are several developed lipid lowering drugs such as statins and fenofibrates, many patients do not achieve an adequate response. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been developed as a new therapeutic strategy for cholesterol regulation. PCSK9 binds to low density lipoprotein receptors (LDLR) and initiates LDLR degradation, elevating LDL-C. Therefore, PCSK9 inhibition could exert beneficial effects on cardiovascular disease outcomes. This review comprehensively summarizes and discusses the effects of PCSK9 inhibitors on lipid metabolism and cardiovascular function comparatively with current lipid lowering drugs. This review also details essential information regarding the cardiovascular benefits of PCSK9 inhibition which could encourage further clinical studies.http://www.sciencedirect.com/science/article/pii/S0753332218347188Proprotein convertase subtilisin/kexin type 9 inhibitorCholesterolCardiovascular functionLow density lipoprotein receptorHeart
collection DOAJ
language English
format Article
sources DOAJ
author Patchareeya Amput
Christian McSweeney
Siripong Palee
Arintaya Phrommintikul
Siriporn C. Chattipakorn
Nipon Chattipakorn
spellingShingle Patchareeya Amput
Christian McSweeney
Siripong Palee
Arintaya Phrommintikul
Siriporn C. Chattipakorn
Nipon Chattipakorn
The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
Biomedicine & Pharmacotherapy
Proprotein convertase subtilisin/kexin type 9 inhibitor
Cholesterol
Cardiovascular function
Low density lipoprotein receptor
Heart
author_facet Patchareeya Amput
Christian McSweeney
Siripong Palee
Arintaya Phrommintikul
Siriporn C. Chattipakorn
Nipon Chattipakorn
author_sort Patchareeya Amput
title The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
title_short The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
title_full The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
title_fullStr The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
title_full_unstemmed The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
title_sort effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2019-01-01
description Low density lipoprotein cholesterol (LDL-C) is a well-established risk factor for cardiovascular disease. Although there are several developed lipid lowering drugs such as statins and fenofibrates, many patients do not achieve an adequate response. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been developed as a new therapeutic strategy for cholesterol regulation. PCSK9 binds to low density lipoprotein receptors (LDLR) and initiates LDLR degradation, elevating LDL-C. Therefore, PCSK9 inhibition could exert beneficial effects on cardiovascular disease outcomes. This review comprehensively summarizes and discusses the effects of PCSK9 inhibitors on lipid metabolism and cardiovascular function comparatively with current lipid lowering drugs. This review also details essential information regarding the cardiovascular benefits of PCSK9 inhibition which could encourage further clinical studies.
topic Proprotein convertase subtilisin/kexin type 9 inhibitor
Cholesterol
Cardiovascular function
Low density lipoprotein receptor
Heart
url http://www.sciencedirect.com/science/article/pii/S0753332218347188
work_keys_str_mv AT patchareeyaamput theeffectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT christianmcsweeney theeffectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT siripongpalee theeffectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT arintayaphrommintikul theeffectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT siriporncchattipakorn theeffectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT niponchattipakorn theeffectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT patchareeyaamput effectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT christianmcsweeney effectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT siripongpalee effectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT arintayaphrommintikul effectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT siriporncchattipakorn effectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
AT niponchattipakorn effectsofproproteinconvertasesubtilisinkexintype9inhibitorsonlipidmetabolismandcardiovascularfunction
_version_ 1721433177260556288

Similar Items